- Home
- TRP vs ALNY Comparison
TRP vs ALNY Comparison
Compare TRP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRP
- ALNY
- Stock Information
- Founded
- TRP 1951
- ALNY 2002
- Country
- TRP Canada
- ALNY United States
- Employees
- TRP N/A
- ALNY N/A
- Industry
- TRP
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- TRP
- ALNY Health Care
- Exchange
- TRP Nasdaq
- ALNY Nasdaq
- Market Cap
- TRP 49.3B
- ALNY 59.1B
- IPO Year
- TRP N/A
- ALNY 2004
- Fundamental
- Price
- TRP $52.07
- ALNY $446.51
- Analyst Decision
- TRP Hold
- ALNY Strong Buy
- Analyst Count
- TRP 3
- ALNY 26
- Target Price
- TRP $62.00
- ALNY $403.20
- AVG Volume (30 Days)
- TRP 1.5M
- ALNY 1.2M
- Earning Date
- TRP 07-31-2025
- ALNY 10-30-2025
- Dividend Yield
- TRP 4.80%
- ALNY N/A
- EPS Growth
- TRP 23.31
- ALNY N/A
- EPS
- TRP 2.99
- ALNY N/A
- Revenue
- TRP $10,486,413,556.00
- ALNY $2,461,963,000.00
- Revenue This Year
- TRP $11.99
- ALNY $58.97
- Revenue Next Year
- TRP $5.28
- ALNY $38.81
- P/E Ratio
- TRP $17.42
- ALNY N/A
- Revenue Growth
- TRP 15.85
- ALNY 5.01
- 52 Week Low
- TRP $40.79
- ALNY $205.87
- 52 Week High
- TRP $52.26
- ALNY $469.81
- Technical
- Relative Strength Index (RSI)
- TRP 66.98
- ALNY 64.99
- Support Level
- TRP $50.36
- ALNY $442.38
- Resistance Level
- TRP $52.10
- ALNY $457.29
- Average True Range (ATR)
- TRP 0.71
- ALNY 11.39
- MACD
- TRP 0.05
- ALNY -4.19
- Stochastic Oscillator
- TRP 92.80
- ALNY 51.46
About TRP TC Energy Corporation
TC Energy operates natural gas, oil, and power generation assets in Canada and the United States. The firm operates more than 60,000 miles of oil and gas pipelines, more than 650 billion cubic feet of natural gas storage, and about 4,300 megawatts of electric power.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.